FY2024 Revision Rates Tallied for Each Firm’s Top 5 Meds; Fuso Logs Price Hike Too on Infusion Products

Many infusion solution products will be subject to unprofitability re-pricing in the FY2024 drug price revision, shows a Jiho survey of the top five products by each pharma company. It was newly found that Fuso Pharmaceutical Industries, an infusion specialist,...read more